BioSpace News Archive

Correvio Pharma Corp. today highlighted that United Therapeutics (NASDAQ: UTHR) has completed its acquisition of SteadyMed Ltd., Correvio’s partner and the licensor of Trevyent®.

Titan Pharmaceuticals, Inc. today announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system.

Leading Companies from Emerging Industries Join Forces to Efficiently Produce High-Purity Cannabinoids at Scale

Acquisition expands geographic presence to Virginia and broadens industrial on-site calibration capabilities

Baxter Canada, a leader in nutrition therapy, today announced Health Canada approval of OLIMEL 7.6% and OLIMEL 7.6% E (amino acids, dextrose, lipids with/without electrolytes, injectable emulsion) for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning and progressing to an incurable stage

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (CSE: FFT.CN) (OTCQX: FFRMF) is pleased to announce that the Company has closed its previously announced spin-out of 11,000,000 common shares of NexTech AR Solutions Corp. (“NexTech”) on a pro rata basis to Future Farm shareholders.

Aflac, the leader in voluntary insurance sales at U.S. worksites, announced today a full slate of activities to honor children and families facing childhood cancer during September, which is National Childhood Cancer Awareness Month.

PolarityTE, Inc. (Nasdaq: COOL) today announced that it will present an abstract entitled, “Regeneration of Full Thickness Hair-Bearing Skin in Chronic Refractory Wounds with an Autologous Homologous Skin Construct: Preclinical and Clinical Experience,” at the 17th Annual National Clinical Conference of the American Professional Wound Care

Today, Eiger BioPharmaceuticals, Inc (NASDAQ: EIGR), a company focused on the development and commercialization of targeted therapies for rare diseases, announced it has received minutes from a pre-investigational new drug (pre-IND) meeting with the Division of Gastroenterology and Inborn Errors Products of the U.S. Food and Drug Administration (FDA) for lonafarnib in the treatment of Hutchinson-Gilford Progeria Syndrome